Founded in 2020, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. is an innovative pharmaceutical company focusing on the development of innovative drugs for autoimmune diseases, which is dedicated to solving patients' unmet needs and improving the quality of human life.
The company is headquartered in Hangzhou, Zhejiang Province, with a medical and R&D centre in Shanghai. The company's self-developed QY201 had won the second prize of the 2020 Hangzhou Overseas High-level Talents Innovation and Entrepreneurship Competition National Finals (first prize of the Life and Health Group), and was supported by the key policies of Hangzhou Linping District. In 2021, the company entered into a strategic cooperation with Beda Pharmaceuticals to jointly promote the clinical translational development of the company's drugs.
Adhering to the value concept of "embracing competition, relentless pursuit, and frank dedication", the company has attracted many talents to join it, and has set up a transformation team with successful experience in new drug research and development, medical transformation, clinical management, and business operation. QY201, QY101 and QY211, which are the first class of innovative drugs with global patents developed by the company, are in the clinical trial stage, and have been approved for more than 30 clinical approvals and more than 10 indications.
The company has been elected as the first vice president of China Dermatology New Drug Alliance (PhDA) to jointly promote the linkage of "government, industry, academia, research and medicine" in dermatology, always focusing on patients' unsatisfied clinical needs, independently researching and developing differentiated molecules, and prospectively laying out the layout of autoimmune diseases, and striving to become a leader in the development of innovative autoimmune disease drugs.
0571-89206095 
No.355 Xingzhong Road, Donghu street, Linping District, Hangzhou, Zhejiang, 311100, China
qiyuanshengwu@enitiatebio.com
Dr. Shen Wang is a world-famous expert in medicinal chemistry, founder of VivaVision Biotech, inventor of lifitegrast, Overseas high-level talents, leading talent of Jiaxing elite, and innovative and entrepreneurial talent of Jiangsu Province. Dr. Shen Wang graduated from the University of Pittsburgh in the United States. He has successively held important R & D positions in well-known international enterprises such as Abbott, Sunesis and Amgen. In 2009, he served as the founder and President of Kanionusa, an overseas subsidiary of Jiangsu Kangyuan Pharmaceutical Co., Ltd., and also served as the chief scientific officer (CSO) of new drug research and development of Jiangsu Kangyuan Pharmaceutical Co., Ltd. With nearly 20 years of R & D and management experience in anti-tumor, immune system regulation, metabolic diseases, antiviral and other fields, he has led his team to develop more than 10 drugs into clinical trials, and two drugs have been approved by FDA, including lifitegrast, the only targeted treatment drug for dry eye approved by FDA in recent ten years, and venetoclax, a benchmark anticancer drug.
Mr. Ding Shizhe graduated from St. Louis University and was the co-founder of Betta capital. Prior to the founding of E-nitiate Biopharmaceuticals, he served as the director of strategic collaboration of Betta pharmaceuticals and the executive deputy general manager of Betta Dream Works Incubator. He lead the efforts in the strategic collaboration with Meryx, Merus, Tyrogenex, Xcovery, Agenus and other domestic and foreign innovative pharmaceutical companies, Ding has rich experience in business management, strategic planning, investment, and financing.
Mr. Zhou Cheng graduated from Zhejiang University and is a Chinese certified public accountant. He has successively worked in Deloitte China and ZHEJIN trust. In 2017, he joined Betta capital as general manager and lead the investment in many high-quality innovative pharmaceutical companies such as Clover Biology (hk.2197), Righton Gene (sh.688217), Mabworks and CentryMed. Zhou also has more than ten years of financial management and investment experience.
Ms. Guo Huijie graduated from Xi'an Jiaotong University and is the Deputy Secretary General of Zhejiang life and Health Industry Innovation Committee. She has successively worked in Bank of Beijing and Sansanhui Asset Management Co., Ltd. and joined Betta capital as the investment director in 2016. Guo has lead the investment in Kintor Pharmaceutical Limited (HK.9939), VivaVision, DoubleRainbow and other high-quality innovative pharmaceutical companies, with more than ten years of experience in operation management, investment and financing.
Mr.Pengfei Liu, doctor of medicinal chemistry, served as project leader and senior project manager in Sundia pharmaceuticals and Viva Biotech. With more than 10 years of experience in drug R&D and project management, he is responsible for the early-stage R&D and overall management of the E-nitiate Bio's current product pipeline.
Ms. Jianhui Li, M.D., Ph.D., was an attending physician in the Department of Rheumatology and Immunology and a visiting scholar at Massachusetts General Hospital, Harvard Medical School. After graduating from Shanghai Jiaotong University School of Medicine with a PhD in Internal Medicine, she worked as an attending physician in the Department of Rheumatology and Immunology at Shanghai Changzheng Hospital of the Second Military Medical University for many years, where she independently supervised the ward treatment team, as well as took charge of outpatient, emergency, inpatient chief physician duties, clinical teaching and participated in several phase III clinical trials as Sub-I. Prior to joining Qiyuan Biologics, she worked for Takeda (China), GSK (China), Sanofi (China), and Shanghai Hengrui Pharmaceuticals. She was responsible for making clinical development strategies of several large and small molecules in the field of autoimmunity, developing new products pre-launch and launch medical strategies, developing studies design of phase I-IV and performing related medical affairs. She has over 10 years work experience in pharmaceutical companies.
Ms. Zhang Qianqian, who graduated in Human Resources with a bachelor's degree, pursued further education at the Institute of Psychology of the Chinese Academy of Sciences. She joined Enitiatebio in June 2021. She has worked in multiple domestic and foreign innovation and entrepreneurship companies, such as Sateri Group Company under Royal Golden Eagle，RGE. With over ten years of experience in human resources management, she brings a wealth of expertise to the team.
Mr.Bao,He graduated from Anhui Medical University, and before joining Qiyuan, he worked for many domestic and international pharmaceutical companies, CROs and biopharmaceutical companies, such as Baxter, Novartis, Wuxi CDS and Kintor Pharma，etc. He has more than 19 years of experience in clinical trial operation and project management.
